TMPRSS6 and IRIDA syndrome: Human genetics informs a potential path to the development of such a treatment, as β-thalassemia patients that harbor loss-of-function variants in TMPRSS6 — which otherwise cause IRIDA (25) — have reduced liver iron (26).